Lv41
403 积分 2021-07-07 加入
Hyodeoxycholic acid ameliorates cholestatic liver fibrosis by facilitating m6A-regulated expression of a novel anti-fibrotic target ETV4
6小时前
待确认
Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up
4天前
已完结
Effectiveness of Fenofibrate in Treatment-Naive Patients With Primary Biliary Cholangitis: A Randomized Clinical Trial
4天前
已完结
Plasma Biomarkers of Senescence in Cholestatic Liver Disease: A Signature of Risk Stratification and Progression
8天前
已完结
Mechanistic Rationale of Seladelpar’s Clinical Efficacy through the Selective PPAR-δ Activation in Primary Biliary Cholangitis
9天前
已完结
E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants
12天前
已完结
The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view
12天前
已完结
The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view
18天前
已关闭
Reply to ‘The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view’
21天前
已关闭
The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view
21天前
已关闭
皖公网安备34019202002308
